CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer

NCT07057349 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer
Unresectable Solid Tumor

Interventions

DRUG: [18F]CSB-321

Sponsor

Cytosite Biopharma Inc.